Here's How to Play Core Labs Stock Ahead of Its Q1 Earnings Release
CLB faces declining revenues, weak margins, geopolitical disruptions and inventory issues, with low dividend yield and overvaluation increasing investor caution.
Is Core Stock Worth Buying After a 27% Surge in 6 Months?
CLB stock is supported by international expansion, proprietary tech and solid cash flow amid competitive pricing, volatile oil prices and geopolitical tensions.
Why Is Core Laboratories (CLB) Down 16% Since Last Earnings Report?
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?
CLB's Q4 Earnings Beat Estimates, Sales Lag, Expenses Increase
Core Laboratories expects Reservoir Description revenues of $82-$85 million and Production Enhancement revenues of $39-$42 million for the first quarter of 2025.
Core Laboratories Inc. (CLB) Q4 2024 Earnings Conference Call Transcript
Core Laboratories Inc. (NYSE:CLB ) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Larry Bruno - Chairman and Chief Executive Officer Gwen Gresham - Senior Vice President and Head, Investor Relations Chris Hill - Chief Financial Officer Conference Call Participants Stephen Gengaro - Stifel Josh Jayne - Daniel Energy Partners David Smith - Pickering Energy Partners Operator Good day, and welcome to the Core Laboratories' Fourth Quarter 2024 Earnings Call. All participants will be in listen-only mode.
Core Laboratories (CLB) Misses Q4 Earnings and Revenue Estimates
Core Laboratories (CLB) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.19 per share a year ago.
Core Laboratories to Post Q4 Earnings: Here's What to Expect
CLB is expected to report higher revenues from the year-ago period's level. However, despite this revenue growth, the company is expected to face increased operating expenses.
Core Laboratories (CLB) Reports Next Week: Wall Street Expects Earnings Growth
Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Hold Strategy is Apt for Core Laboratories Stock Now
CLB benefits from strong international growth, high-margin projects and an efficient business model. However, stock underperformance, competition and U.S. market challenges pose risks.
Is Now the Right Time to Buy Core Laboratories After Its 12% YTD Rise?
CLB shows strong earnings growth, solid cash flow and innovative technologies, but faces risks from geopolitical tensions, weak U.S. onshore activity and oil price volatility.
Why Is Core Laboratories (CLB) Up 11.5% Since Last Earnings Report?
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?
Is the Options Market Predicting a Spike in CORE LABS INC (CLB) Stock?
Investors need to pay close attention to CORE LABS INC (CLB) stock based on the movements in the options market lately.
